Australia markets closed
  • ALL ORDS

    7,270.00
    +3.40 (+0.05%)
     
  • ASX 200

    7,068.80
    +3.60 (+0.05%)
     
  • AUD/USD

    0.6443
    +0.0026 (+0.40%)
     
  • OIL

    90.33
    +0.70 (+0.78%)
     
  • GOLD

    1,944.90
    +5.30 (+0.27%)
     
  • Bitcoin AUD

    41,223.68
    -106.38 (-0.26%)
     
  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     
  • AUD/EUR

    0.6049
    +0.0036 (+0.60%)
     
  • AUD/NZD

    1.0810
    -0.0001 (-0.01%)
     
  • NZX 50

    11,372.62
    +53.88 (+0.48%)
     
  • NASDAQ

    14,701.10
    +6.85 (+0.05%)
     
  • FTSE

    7,683.91
    +5.29 (+0.07%)
     
  • Dow Jones

    33,963.84
    -106.58 (-0.31%)
     
  • DAX

    15,557.29
    -14.57 (-0.09%)
     
  • Hang Seng

    18,057.45
    +402.04 (+2.28%)
     
  • NIKKEI 225

    32,402.41
    -168.62 (-0.52%)
     

Treace Medical Concepts, Inc. (NASDAQ:TMCI) is largely controlled by institutional shareholders who own 58% of the company

Key Insights

  • Given the large stake in the stock by institutions, Treace Medical Concepts' stock price might be vulnerable to their trading decisions

  • A total of 9 investors have a majority stake in the company with 50% ownership

  • Insiders have been selling lately

If you want to know who really controls Treace Medical Concepts, Inc. (NASDAQ:TMCI), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 58% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.

Let's delve deeper into each type of owner of Treace Medical Concepts, beginning with the chart below.

See our latest analysis for Treace Medical Concepts

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Treace Medical Concepts?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Treace Medical Concepts. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Treace Medical Concepts' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Treace Medical Concepts is not owned by hedge funds. With a 18% stake, CEO John Treace is the largest shareholder. Meanwhile, the second and third largest shareholders, hold 6.3% and 5.2%, of the shares outstanding, respectively.

We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Treace Medical Concepts

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own a reasonable proportion of Treace Medical Concepts, Inc.. It has a market capitalization of just US$1.6b, and insiders have US$517m worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 10% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Treace Medical Concepts. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Treace Medical Concepts has 2 warning signs we think you should be aware of.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here